Efficacy and safety of tenecteplase in Indian elderly STEMI patients from the Elaxim Indian Registry.
OBJECTIVE
To analyze the efficacy and safety of indigenous Tenecteplase in Indian elderly STEMI patients in a clinical setting.


METHODS
Post-licensure, observational, prescription event monitoring (PEM) study.


RESULTS
2162 patients received weight-adjusted Tenecteplase injection. The data for elderly (> 60 years) and non-elderly (< or = 60 years) was identified, segregated and compared. Out of 2162 patients, 805 were elderly patients and 1357 were non-elderly. Clinically successful thromolysis was seen in 83.98% of elderly and 86% of non-elderly group (p = 0.22). There was no significant difference in percentage of patients reporting bleeding, stroke, intracranial hemorrhage, myocardial reinfraction, ventricular tachyarrhythmia between the groups. Mortality was significantly (p = < 0.0001) more in elderly (6.21%) than non-elderly (2.06%) patients.


CONCLUSIONS
The indigenously developed Tenecteplase shows high efficacy and safety in its in-hospital use in Indian elderly patients with STEMI.
Department of Cardiology, Manipal Heart Institute, Bangalore, Karnataka, India. drismurthy@gmail.com
I
I
Sathyamurthy
C G
CG
Bahuleyan
Arun
A
Srinivas
Milind
M
Gadkari
Soumitra
S
Kumar
G
G
Ratnaparkhi
Uday
U
Mahurkar
D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing; D012042:Registries; D000077785:Tenecteplase; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D000077785:Tenecteplase